Vermillion, Inc. (VRML) insider have most recently took part in a trading activity. On Aug 23, 2017 Palmieri Valerie Barber, President and CEO bought 768 shares having total worth of $998 at the price of $1.3 per share, following the transaction a total of 59,865 shares owned by Palmieri Valerie Barber. Before this latest buy, Palmieri Valerie Barber purchased VRML at 2 other times during the past twelve months, for a total investment of $15,058 at an average of $1.6 per share.
Furthermore, over the past 12 months , the stock was traded 10 times by insiders. an employee of the company was the buyer in 10 instances.
Shares of Vermillion, Inc. (VRML) traded down 2.34% on Aug 23, 2017, hitting $1.25. 31,141 shares of the company’s stock traded hands. Vermillion, Inc. has a 52 week low of $0.89 and a 52 week high of $2.62. The company’s market cap is $72 million.
Vermillion, Inc. (VRML) last announced its earnings results on Aug 9, 2017. The company reported -0.04 earnings per share (EPS) for the quarter, same as the consensus estimate of -0.04. The company had revenue of $1 million for the quarter, compared to the consensus estimate of $1 million. During the same quarter in the previous year, the company posted -0.07 earnings per share. The company’s revenue for the quarter was up 27% on a year-over-year basis.
|earnings per share||-0.04||0.00||-0.05||-0.05||-0.07||-0.07||-0.09||-0.10||-0.10||-0.11|
Vermillion, Inc., was originally incorporated in California on December 9, 1993, under the name Abiotic Systems. In March 1995, Abiotic Systems changed its corporate name to Ciphergen Biosystems, Inc. and on June 21, 2000, it reincorporated in Delaware. The Company is engaged in discovery; development and commercialization of novel high-value diagnostic tests that help physicians diagnose, treat and improve outcomes for patients. It uses the process of utilizing advanced protein separation methods to identify and resolve variants of specific biomarkers for developing a procedure to measure a property or concentration of an analyte, known as an ‘assay’ and commercializing novel diagnostic tests. The Company’s product, OVA1, was cleared by the United States Food and Drug Administration (FDA) on September 11, 2009. OVA1 addresses a clear unmet clinical need, namely the pre-surgical identification of women who are at high risk of having a malignant ovarian tumor. The Company has development programs in other clinical aspects of ovarian cancer as well as in peripheral arterial disease. In the field of peripheral arterial disease, it has identified candidate biomarkers that may help to identify individuals at high risk for a decreased ankle-brachial index score, which is indicative of the likely presence of peripheral arterial disease. It has recently completed an intended-use study to develop and validate a multi-marker algorithm for the assessment of individuals at risk for peripheral arterial disease. This algorithm will be specifically directed at a primary care population in which the peripheral arterial disease blood test (VASCLIR) is expected to be used. Current and former academic and research institutions that the Company has collaborations with include The Johns Hopkins University School of Medicine; The University of Texas M.D. Anderson Cancer Center; University College London; The University of Texas Medical Branch ‘UTMB’; The Katholieke Universiteit Leuven; Clinic of Gynecology and Clinic of Oncology, Rigshospitalet, Copenhagen University Hospital; The Ohio State University Research Foundation; and Stanford University. The Company has been subject to licensing and regulation under federal, state and local laws relating to the handling and disposal of medical specimens and hazardous waste as well as to the safety and health of laboratory employees.
Latest posts by William White (see all)
- Insider Activity to Watch: Hooper Holmes, Inc. $HPHW - November 24, 2017
- Recent Insider Activity: EnSync, Inc. $ESNC - November 24, 2017
- Recent Insider Activity: IsoRay, Inc. $ISR - November 24, 2017